Circumvention of 5-Fluorouracil Resistance in Human Stomach Cancer Cells by Uracil Phosphoribosyltransferase Gene Transduction

Makoto Inaba,1 Hiroko Sawada,1 Akiko Sadata2 and Hirofumi Hamada2, 3

1Division of Experimental Chemotherapy and 2Department of Molecular Biotherapy Research, Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 1-37-1 Kami-Ikebukuro, Toshima-ku, Tokyo 170-8455

A human stomach cancer cell line with acquired resistance to 5-fluorouracil (5-FU), NUGC-3/5FU/L, has been found to possess reduced ability to convert 5-FU into active metabolites. We attempted in vitro gene therapy for this 5-FU-resistant cell line. NUGC-3 and NUGC-3/5FU/L cells were infected with recombinant adenovirus (Ad) containing *Escherichia coli* uracil phosphoribosyltransferase (UPRT) gene driven by CAG promoter (CA), AdCA-UPRT, and changes in their 5-FU metabolism and sensitivity were investigated. Activities of orotate phosphoribosyltransferase increased from 10.2 and 1.56 (nmol/mg protein/30 min) in the uninfected cells of NUGC-3 and NUGC-3/5FU/L to 21.4. The 50% growth-inhibition concentration (IC50) was 12.7 µM for NUGC-3 and much higher than 100 µM/mg protein in NUGC-3 cells on infection with AdCA-UPRT, and in NUGC-3/5FU/L cells it increased from 1.91 to 21.4. The 50% growth-inhibition concentration (IC50) was 12.7 µM/liter for NUGC-3 and much higher than 100 µM/liter for NUGC-3/5FU/L, indicating over 8-fold resistance. NUGC-3/5FU/L transfected with the UPRT gene showed very high sensitivity to 5-FU with an IC50 of 3.2 µM/liter. The high resistance in this metabolic activation-deficient cell line was thus completely reversed by transduction of an exogenous gene coding for a 5-FU-anabolizing enzyme.

Key words: 5-Fluorouracil — Uracil phosphoribosyltransferase — Drug resistance — Gene therapy — Adenoviral vector

It is widely known that 5-FU is effective against colorectal, stomach, head and neck, breast and other cancers; in particular it is the only drug useful for colorectal cancer. However, its efficacy is often hampered by the appearance of acquired resistance of tumor cells to 5-FU. The biochemical mechanisms of 5-FU resistance in human gastro-intestinal cancer cells which acquire resistance during repeated *in vitro* exposure to this drug include weaker inhibition of TS via decreased folylpolyglutamate synthetase expression,5, 6) TS gene amplification,5, 4) and reduced activity of 5-FU-anabolizing enzymes.5, 6) We also established 5-FU-resistant sublines of three different human colon and stomach cancer cell lines, and found that poor conversion of 5-FU into its active metabolites due to reduced activity levels of enzymes involved in pyrimidine nucleotide synthesis is a major mechanism of resistance.7-9) Reversal of drug resistance is an intriguing subject, and several successful approaches, at least experimentally, have been reported in the field of P-glycoprotein-associated multidrug resistance. However, few approaches to overcoming resistance to 5-FU have been reported, probably due to difficulty in modulating 5-FU-activating enzyme activity.

In recent years, various approaches to gene therapy for cancers have been reported.10) One major chemotherapeutic approach is conversion of a nontoxic prodrug into a toxic metabolite by the transfection of a so-called suicide enzyme gene, and two combination modalities, herpes simplex virus thymidine kinase with gancyclovir and *E. coli* cytosine deaminase with 5-fluorocytosine, have been widely tested. Studies on enhancing the sensitivity of human tumor cells to ara-C by transfer of deoxyctydine kinase gene have also been conducted.11, 12) Very recently, we reported a novel approach for sensitizing various human cancer cell lines to 5-FU by transfection of the *E. coli* UPRT gene.13) This enzyme corresponds to OPRT in mammalian cells, and directly converts 5-FU into FUMP in the presence of PRPP as a
co-substrate. FUMP is further metabolized into two major active metabolites, FlUUMP and FUTP. In our previous report, we demonstrated that adenovirus-mediated transduction of the UPRT gene results in marked sensitization of colon, gastric, liver, and pancreas cancer cells to low concentrations of 5-FU. It remained to be determined whether this gene therapy approach is also effective to overcome the 5-FU resistance of cancer cells. In the present study, we used a 5-FU-resistant subline of human stomach cancer NUGC-3 cells, which are deficient in metabolic activation of 5-FU due to relatively low activity levels of uridine phosphorylase and kinase and OPRT compared to the parent line, and infected these cells with AdCA-UPRT in an attempt to reverse the 5-FU resistance by introducing a transgene of a 5-FU-anabolizing enzyme.

MATERIALS AND METHODS

Chemicals [3H]5-FU (462.5 GBq/mmol) was purchased from NEN Life Science Products (Wilmington, DE). MTT was from Sigma Chemical Co. (St. Louis, MO). All other chemicals were of analytical grade.

Cell lines NUGC-3, a human stomach cancer cell line, was obtained from Japanese Cancer Research Resources Bank (Tokyo). Its 5-FU-resistant subline, NUGC-3/5-FU/L, was established by repeated 5-day exposures of NUGC-3 cells to stepwisely increasing concentrations of 5-FU, as previously reported. Cells were cultured in RPMI 1640 (Nissui Pharmaceutical Co., Ltd., Tokyo) supplemented with 10% fetal bovine serum (M. A. Bioproducts, Walkersville, MD), 1% antibiotic antymycotic solution (Sigma) and 0.9 mg/ml amphotericin B (solubilized) (Sigma).

Adenovirus infection in vitro The recombinant adenovirus containing the lacZ or UPRT gene driven by the CAG promoter, AdCA-lacZ or AdCA-UPRT, was prepared as described in our previous report. Infection was performed by incubating cells with AdCA-lacZ or AdCA-UPRT for 1 h and washing them with the complete culture medium.

Assays for β-gal Cells were plated in 96-well flat-bottomed plates so as to make 5,000 cells/100 μl/well, incubated with AdCA-lacZ at an MOI of 10–100 for 1 h, and cultured for a further 48 h to allow adequate expression of the transduced gene. Cells were washed with PBS and fixed in PBS containing 0.5% glutaraldehyde for 10 min. The cells were rinsed in PBS containing 1 mmol/liter MgCl2 and incubated for 1 h in PBS containing 5 mmol/liter K2Fe(CN)6, 5 mmol/liter K4Fe(CN)6, 1 mmol/liter MgCl2 and 1 mg/ml 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-gal; Wako Pure Chemical Industries, Ltd., Tokyo). The cells were washed with PBS, and β-gal-positive cells per 100 cells were counted. Six hundred cells were counted in total.

Assay of enzymatic conversion of 5-FU into its nucleotides Twenty-four hours after plating, cells were infected with AdCA-UPRT at an MOI of 100 for 1 h, and cultured in fresh medium for a further 48 h. Cytosol as an enzyme source was obtained from both uninfected and adenovirus-infected cells by sonicating them in homogenate buffer (50 mmol/liter Tris-HCl, 1 mmol/liter EDTA and 5 mmol/liter MgCl2; pH 7.4) at maximum output (Sonifier cell disrupter 350; Smith-Kline), and centrifuging the homogenate at 75,000g at 4°C for 20 min in a Beckman ultracentrifuge (model TL-100; Fullerton, CA). The reaction mixture for measuring direct conversion of 5-FU into FUMP by UPRT (including OPRT) consisted of 0.5 mmol/liter [3H]5-FU, 2 mmol/liter PRPP, 5 mmol/liter MgCl2, 15 mmol/liter 2-glycerophosphate, 0.6 mmol/liter α,β-methyleneadenosine diphosphate and 50 mmol/liter Tris-HCl (pH 8.0). The reaction mixture for measuring the two-step conversion by uridine phosphorylase and kinase consisted of 0.5 mmol/liter [3H]5-FU, 5 mmol/liter ribose-1-phosphate, 5 mmol/liter ATP, 5 mmol/liter MgCl2, and 15 mmol/liter 2-glycerophosphate. These mixtures were incubated at 37°C with 40–50 μl of the cytosol in a total volume of 100 μl for 30 min, and the reaction was stopped by heating them at 90–100°C. After centrifugation at 14,000 rpm for 2 min in a Tomy model MR-150 centrifuge (Tokyo), 20 μl of the supernatant was charged with cold carrier on a PEI-cellulose thin-layer chromatography sheet (Merck, #1-05579, Frankfurt, Germany) and developed with water. The spots of substrate and product were distinguished under UV and excised. The radioactivity level in each was measured using a Beckman model LS 7500 scintillation counter. The protein content was measured using the BCA protein assay reagent (Pierce Chemical Co., Rockford, IL).

Assay for intracellular 5-FU nucleotides Twenty-four hours after 2.5×105 cells had been plated in 60 mm dishes, they were infected with either AdCA-lacZ or AdCA-UPRT at an MOI of 100 for 1 h. After 48 h culture, they were exposed to 1 μmol/liter [3H]5-FU for 30 min. Cells were washed twice with PBS, and separated into acid-insoluble and -soluble fractions by treatment with 5% trichloroacetic acid. The acid-soluble fraction (20 μl) was charged on a PEI-cellulose thin-layer chromatography sheet (Merck, #1-05579, Frankfurt, Germany) and developed with water. The spot of 5-FU nucleotides was distinguished under UV and excised. The acid-insoluble fraction was solubilized in 99% formic acid. According to our previous experience and also that of other researchers, more than 90% of the 5-FU uptake in the acid-insoluble fraction during the early period (30 min) is incorporated into RNA. The radioactivity levels were measured using a scintillation counter. The protein content of both fractions was also measured.

Drug sensitivity assays Cells were plated at a density of 5×103/100 μl in 96-well plates. Twenty-four hours later,
the cells were infected with AdCA-lacZ or AdCA-UPRT at an MOI of 100 for 1 h and then cultured with various concentrations of 5-FU for 120 h. Cell growth was measured by means of a partially modified MTT assay:\(^{18}\); cells were incubated in 100 µl of MTT solution (50 µg of MTT, 0.1 mg of glucose, 0.08 µmol of MgSO\(_4\), 225 µg of NaHCO\(_3\), 0.5 µmol of HEPES/100 µl of PBS(−)) for 1 h at 37°C, and shaken for 10 min after addition of 100 µl of ethanol to solubilize the formazan formed. The optimal densities were read on an automated spectrophotometric plate reader at a single wavelength of 540 nm.

RESULTS

The infection efficiency of recombinant adenovirus was examined by treating cells with AdCA-lacZ at various doses, followed by X-gal staining. As shown in Fig. 1, almost all cells treated with AdCA-lacZ at an MOI of 100 expressed β-gal activity in both NUGC-3 and NUGC-3/5FU/L lines. Based on this result, an MOI of 100 was determined as optimal. By using cytosol prepared from NUGC-3 and NUGC-3/5FU/L cells infected with mock or AdCA-UPRT as an enzyme source, the activity of the enzyme catalyzing the direct conversion of 5-FU into FUMP with PRPP as a co-substrate was compared between the control and AdCA-UPRT-infected cells. AdCA-lacZ-infected cells could not be used as a control because an extremely large amount of AdCA-lacZ would have been needed for this experiment. As is clearly demonstrated in Fig. 2A, high activity levels were observed with the infected cells of both lines: the degrees of elevation were 21- and 152-fold in NUGC-3 and NUGC-3/5FU/L cells, respectively. Activity of uridine phosphorylase plus uridine kinase was also measured using ribose-1-phosphate and ATP as co-substrates (Fig. 2B). No difference was found between the control and AdCA-UPRT-infected NUGC-3 cells, but the infected NUGC-3/5FU/L cells showed 4.7-fold more activity than the control.

Cells infected with AdCA-lacZ as a control or AdCA-UPRT were exposed to 1 µmol/liter 5-FU for 30 min and intracellular levels of 5-FU nucleotides were compared. 5-FU nucleotides in the acid-insoluble fraction, which seem

![Fig. 1. In vitro gene transduction efficacy of recombinant adenovirus. NUGC-3 (○) and NUGC-3/5FU/L (●) cells were infected with AdCA-lacZ at an MOI of 10–1,000. After X-gal staining, the β-gal-positive cells were enumerated. Each point is the mean of 6 determinations with the SD shown by a bar.](image)

![Fig. 2. Enzymatic conversion of 5-FU into its nucleotides by cytosol from control and AdCA-UPRT-infected cells. The cytosol and [3H]5-FU were incubated with PRPP (A) or ribose-1-phosphate and ATP (B) as co-substrates for 30 min. The open (NUGC-3) and solid black (NUGC-3/5FU/L) columns represent the mean enzymatic activities of 3 determinations with the SD values shown by bars.](image)

![Fig. 3. Intracellular formation of 5-FU nucleotides from 5-FU in control and AdCA-UPRT-infected cells. AdCA-lacZ-infected cells were used as the control. Cells were incubated with 1 µM [3H]5-FU for 30 min, and fractionated into acid-insoluble (A) and -soluble (B) fractions. The open (NUGC-3) and solid black (NUGC-3/5FU/L) columns represent the mean 5-FU nucleotide level of 3 determinations with the SD values shown by bars.](image)
to include FdUMP consisting of covalent ternary complex of TS and FUTP incorporated into cellular RNA, amounted to $7.32 \pm 1.26$ and $1.91 \pm 0.20 \,(pmol/mg \, protein)$ in the control NUGC-3 and NUGC-3/5FU/L cells, respectively (Fig. 3A). The infection with AdCA-UPRT increased the level of 5-FU nucleotides in the acid-insoluble fraction by 2.2- and 5.4-fold in NUGC-3 and NUGC-3/5FU/L cells, respectively. The level in NUGC-3/5FU/L cells was rather high compared to the parent NUGC-3 cells.

5-FU nucleotides in the acid-soluble fraction were also compared (Fig. 3B). Levels of acid-soluble 5-FU nucleotides, including free FdUMP and FUTP, in the AdCA-UPRT-infected cells showed 38.5- and 66.9-fold elevation compared with the control cells in NUGC-3 and NUGC-3/5FU/L, respectively. The ratios of total 5-FU nucleotide of the AdCA-UPRT-infected/control cells were 2.76 and 13.5 in NUGC-3 and NUGC-3/5FU/L, respectively.

Cells were infected with mock, AdCA-UPRT or AdCA-lacZ at an MOI of 100 for 1 h and then cultured with various concentrations of 5-FU for 120 h. As shown in Fig. 4, the IC$_{50}$ values for uninfected NUGC-3 and NUGC-3/5FU/L cells were 12.7 µmol/liter and much higher than 100 µmol/liter, respectively; thus NUGC-3/5FU/L was at least 8-fold more resistant to 5-FU. However, when NUGC-3/5FU/L was treated with AdCA-UPRT, its IC$_{50}$ shifted to 3.2 µmol/liter which was significantly lower than that of uninfected NUGC-3 cells. It should be noted that not only NUGC-3/5FU/L but also NUGC-3 cells were significantly sensitized. They were scarcely affected by infection with AdCA-lacZ.

**DISCUSSION**

Defective anabolism into active nucleotides seems to play a major role in resistance to anticancer agents related to purine and pyrimidine. Reduced activity of deoxycytidine kinase has been reported to be a major mechanism of resistance to ara-C[19] and gemcitabine.[20] In the case of resistance to 5-FU, poor activity of several enzymes involved in the anabolism of 5-FU has also been demonstrated.[5–9] Clinically, the relationship between response to 5-FU-based chemotherapy and content or activity of TS in tumor tissue has been extensively investigated. Most tumors with a relatively high content of TS are less responsive to 5-FU, though tumors with low TS content are not necessarily responsive.[21, 22] This strongly suggests that, in addition to TS content, capacity for metabolism of 5-FU into its nucleotides in individual tumors is profoundly related to the clinical response to 5-FU.

Experimentally, only transfection of an exogenous gene coding for the corresponding anabolic enzyme is thought to be effective for reversing this type of resistance. In the case of ara-C resistance, Stegmann et al.[23] attempted the transfection of deoxycytidine kinase gene into an ara-C-resistant rat leukemic cell line and succeeded in completely reversing a more than 9,000-fold resistance to ara-C. In the present study, we tried to transfect the *E. coli* UPRT gene into 5-FU-resistant human stomach cancer cells, which are deficient in 5-FU anabolism, with the aim of reversing 5-FU resistance *in vitro*.

Cytosol prepared from both NUGC-3 and NUGC-3/5FU/L cells infected with AdCA-UPRT showed surprisingly high activity levels of UPRT (including a relatively small amount of cellular intrinsic OPRT) as compared with the control cells (Fig. 2A). Intracellular acid-insoluble and -soluble 5-FU nucleotide levels were also increased by infection with AdCA-UPRT in both cell lines (Fig. 3), but the degree of elevation was not as large as for the UPRT activity. This indicates that intracellular formation of 5-FU nucleotides is limited by the intracellular PRPP level, even though an enormous amount of UPRT protein is expressed after the transfection. It should be noted that the lower 5-FU nucleotide levels in the acid-insoluble and soluble fractions in NUGC-3/5FU/L cells increased substantially relative to those in NUGC-3 cells after the infection with AdCA-UPRT (Fig. 3).

Based on these biochemical results, we assessed the sensitivity to 5-FU of uninfected and AdCA-UPRT-infected cells in a 120-h drug exposure assay (Fig. 4). NUGC-3/5FU/L cells were sensitized more than 31-fold by infection with AdCA-UPRT, and as a result became 4-fold more sensitive than the original NUGC-3 cells. This
clearly indicates that transfection of the *E. coli UPRT* gene completely reversed the high degree of 5-FU resistance in NUGC-3/5FU/L cells by increasing the intracellular level of active 5-FU nucleotides.

The parent NUGC-3 cells were also sensitized by infection with AdCA-UPRT, and the infected cells became 47-fold more sensitive than the uninfected ones (Fig. 4). It seems difficult to explain fully the marked sensitization induced by an about 2-fold increase in acid-insoluble levels of 5-FU nucleotide on infection with AdCA-UPRT (Fig. 3A). The results in Fig. 3 were obtained after only 30 min incubation of cells with 1 μmol/liter 5-FU. Taking this into consideration, we speculate that the 5-FU nucleotide, particularly FdUMP, level in the acid-soluble rather than -insoluble fraction makes a major contribution to the prolonged inhibition of TS, because DNA-directed action seems predominant during long-term 5-FU exposure.1, 24, 25

Another point to be discussed is that even after infection with AdCA-UPRT, NUGC-3/5FU/L was more resistant than NUGC-3, although the degree of resistance in the infected cell lines is lower than in the uninfected ones. This could not be explained by the 5-FU nucleotide level in either the acid-insoluble or -soluble fraction of the AdCA-UPRT-infected NUGC-3 and NUGC-3/5FU/L cells. Little is known about the molecular species in the acid-soluble fraction. If the FdUMP level in the acid-soluble fraction of NUGC-3 cells is significantly higher than that of NUGC-3/5FU/L cells, this might explain the difference in sensitivity between the AdCA-UPRT-infected NUGC-3 and NUGC-3/5FU/L cells. In this case, it is possible that ribonucleotide reductase is partially responsible for the high degree of resistance in NUGC-3/5FU/L cells, by diminishing the flow from FUMP to FdUMP.

In conclusion, the very high 5-FU-resistance in human stomach cancer NUGC-3/5FU/L cells, which have poor activities of uridine phosphorylase/kinase and OPRT, was completely reversed by adenovirus-mediated transduction of the *E. coli UPRT* gene. This methodology could be applicable to treat various 5-FU-resistant cancers. Further, the amount of 5-FU could be reduced to avoid undesirable side effects if the combination of 5-FU and this gene therapy were introduced for routine therapy.

(Received October 8, 1998/Revised November 19, 1998/ Accepted December 8, 1998)

REFERENCES

1) Aschele, C., Sobrero, A., Faderan, M. A. and Bertino, J. R. Novel mechanism(s) of resistance to 5-fluorouracil in human colon cancer (HCT-8) sublines following exposure to two different clinically relevant dose schedules. *Cancer Res.*, 52, 1855–1864 (1992).

2) Wang, F-S., Aschele, C., Sobrero, A., Chang, Y-M. and Bertino, J. R. Decreased folypolyglutamate synthetase expression: a novel mechanism of fluorouracil resistance. *Cancer Res.*, 53, 3677–3680 (1993).

3) Lesuffleur, T., Kornowski, A., Luccioni, C., Muleris, M., Barbat, A., Beaumatin, J., Dussaulx, E., Dutrillaux, B. and Zweibaum, A. Adaptation to 5-fluorouracil of the heterogenous human colon tumor cell line HT-29 results in the selection of cells committed to differentiation. *Int. J. Cancer*, 49, 721–730 (1991).

4) Copur, S., Alba, K., Drake, J. C., Allegra, C. J. and Chu, E. Thymidylate synthase gene amplification in human colon cancer cell lines resistant to 5-fluorouracil. *Biochem. Pharmacol.*, 49, 1419–1426 (1995).

5) Pizzorno, G. and Handschumacher, R. E. Effect of clinically modeled regimens on the growth response and development of resistance in human colon carcinoma cell lines. *Biochem. Pharmacol.*, 49, 559–565 (1995).

6) Findenig, G., Mader, R. M., Fritzer-Szekeres, M., Steger, G. G., Jaeger, W. and Szekeres, T. Modulation of 5-fluorouracil resistance in human colon tumor cell lines by azido-thymidine. *Oncol. Res.*, 8, 189–196 (1996).

7) Inaba, M., Mitsuhashi, J., Sawada, H., Miike, N., Naoe, Y., Daimon, A., Koizumi, K., Tsujimoto, H. and Fukushima, M. Reduced activity of anabolizing enzymes in 5-fluorouracil-resistant human stomach cancer cells. *Jpn. J. Cancer Res.*, 87, 212–220 (1996).

8) Inaba, M., Tanaka, T. and Sawada, H. Increased sensitivity to long-term 5-fluorouracil exposure of human colon cancer HT-29 cells resistant to short-term exposure. *Jpn. J. Cancer Res.*, 89, 323–327 (1998).

9) Inaba, M., Naoe, Y. and Mitsuhashi, J. Mechanisms for 5-fluorouracil resistance in human colon cancer DLD-1 cells. *Biol. Pharm. Bull.*, 21, 569–573 (1998).

10) Roth, J. A. and Cristiano, R. J. Gene therapy for cancer: what have we done and where are we going? *J. Natl. Cancer Inst.*, 89, 21–39 (1997).

11) Hapke, D. M., Stegmann, A. P. A. and Mitchell, B. S. Retroviral transfer of deoxycytidine kinase into tumor cell lines enhances nucleoside toxicity. *Cancer Res.*, 56, 2343–2347 (1996).

12) Manome, Y., Wen, P. Y., Dong, Y., Tanaka, T., Mitchell, B. S., Kufe, D. W. and Fine, H. A. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytotoxic arabinoside in vivo and in vitro. *Nat. Med.*, 2, 567–573 (1996).

13) Kanai, F., Kawakami, T., Hamada, H., Sadata, A., Yoshida, Y., Tanaka, T., Ohashi, M., Shiratori, Y. and Omata, M. Adenovirus-mediated transduction of *Escherichia coli* uracil phosphoribosyl-transferase gene sensitizes cancer cells to low concentration of 5-fluorouracil in vitro and in vivo. *Cancer Res.*, 58, 1946–1951 (1998).

14) Kanai, F., Shiratori, Y., Yoshida, Y., Wakimoto, H.,...
Hamada, H., Kanegae, Y., Saito, I., Nakabayashi, H., Tamaoki, T., Tanaka, T., Lan, K.-H., Kato, N., Shiina, S. and Omata, M. Gene therapy for α-fetoprotein producing human hepatoma cells by adenovirus-mediated transfer of herpes simplex virus thymidine kinase gene. *Hepatology*, 23, 1359–1368 (1996).

15) Tanaka, T., Kanai, F., Okabe, S., Yoshida, Y., Wakimoto, H., Hamada, H., Shiratori, Y., Lan, K.-H., Ishitobi, M. and Omata, M. Adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing human gastric carcinoma cells in vitro. *Cancer Res.*, 56, 1341–1345 (1996).

16) Peters, G. J., Laurensse, E., Leyva, A., Lankelma, J. and Pinedo, H. M. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5′-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. *Cancer Res.*, 46, 20–28 (1986).

17) Loenn, U. and Loenn, S. Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. *Cancer Res.*, 44, 3414–3418 (1984).

18) Carmichael, J., DeGraff, W. G., Gazdar, A. F., Minutena, J. D. and Mitchell, J. B. Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. *Cancer Res.*, 48, 589–601 (1988).

19) Grant, S. Ara-C: cellular and molecular pharmacology. In “Advances in Cancer Research,” vol. 72, ed. G. F. V. Woude and G. Klein, pp. 197–233 (1998). Academic Press, New York.

20) Ruiz van Haperen, V. W. T., Veerman, G., Eriksson, S., Boven, E., Stegmann, A. P. A., Hermens, M., Vermorken, J. B., Pinedo, H. M. and Peters, G. J. Development and molecular characterization of a 2′,2′-difluorodeoxycytidine-resistant variant of the human ovarian carcinoma cell line A2780. *Cancer Res.*, 54, 4138–4143 (1994).

21) Lenz, H.-J., Leichman, C. G., Danenberg, K. D., Groshen, S., Cohen, H., Laine, L., Crookes, P., Silberman, H., Baranda, J., Garcia, Y., Li, J. and Leichman, L. Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. *J. Clin. Oncol.*, 14, 176–182 (1996).

22) Leichman, C. G., Lenz, H.-J., Leichman, L., Danenberg, K., Baranda, J., Groshen, S., Boswell, W., Metzger, R., Tan, M. and Danenberg, P. V. Quantitation of intratumoral thymidylate synthase expression predicts for disseminated colorectal cancer response and resistance to protracted-infusion fluorouracil and weekly leucovorin. *J. Clin. Oncol.*, 15, 3223–3229 (1997).

23) Stegmann, A. P. A., Honders, W. H., Willemze, R., Ruiz van Haperen, V. W. T. and Landegent, J. E. Transfection of wild-type deoxycytidine kinase (dck) cDNA into an ara-C and DAC-resistant rat leukemia cell line of clonal origin fully restores drug sensitivity. *Blood*, 85, 1188–1194 (1995).

24) Inaba, M., Mitsuhashi, J. and Ozawa, S. Kinetic analysis of 5-fluorouracil action against various cancer cells. *Ipn. J. Cancer Res.*, 81, 1039–1044 (1990).

25) Inaba, M. and Mitsuhashi, J. Flow cytometric analysis of cell-killing actions of 5-fluorouracil in human colorectal cancer cells. *Oncol. Res.*, 6, 303–309 (1994).